Sagar Lonial

List of Publications by Citations

413 papers	34,152 citations	68 h-index	182 g-index
430 ext. papers	40,014 ext. citations	5.7 avg, IF	6.41 L-index

#	Paper	IF	Citations
413	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
412	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	10.2	2783
411	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology, The*, **2014**, 15, e538-48	21.7	2253
410	Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *New England Journal of Medicine*, **2005**, 352, 2487-98	59.2	2097
409	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncology, The*, **2016**, 17, e328-e346	21.7	1155
408	Initial genome sequencing and analysis of multiple myeloma. *Nature*, **2011**, 471, 467-72	50.4	1117
407	Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. *New England Journal of Medicine*, **2007**, 357, 2133-42	59.2	1057
406	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *Journal of Clinical Oncology*, **2015**, 33, 2863-9	2.2	976
405	Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *New England Journal of Medicine*, **2015**, 373, 621-31	59.2	935
404	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood*, **2011**, 117, 4691-5	2.2	681
403	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood*, **2010**, 116, 679-86	2.2	680
402	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. *Cancer Cell*, **2014**, 25, 91-101	24.3	657
401	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 1195-206	21.7	604
400	Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. *Journal of Clinical Oncology*, **2006**, 24, 4867-74	2.2	600
399	Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. *Lancet, The*, **2016**, 387, 1551-1560	40	581
398	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580
397	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood*, **2012**, 120, 2817-25	2.2	544

396	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood*, **2016**, 127, 2955-62	2.2	463
395	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. *Blood*, **2007**, 110, 3557-60	2.2	443
394	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood*, **2015**, 125, 2068-74	2.2	426
393	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. *Blood*, **2017**, 130, 974-981	2.2	312
392	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *New England Journal of Medicine*, **2021**, 384, 705-716	59.2	287
391	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncology, The*, **2020**, 21, 207-221	21.7	281
390	Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. *Blood*, **2005**, 106, 3777-84	2.2	278
389	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. *Lancet Oncology, The*, **2017**, 18, e206-e217	21.7	275
388	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. *Blood*, **2016**, 128, 37-44	2.2	272
387	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. *Blood*, **2014**, 123, 1826-32	2.2	271
386	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. *Haematologica*, **2013**, 98, 1753-61	6.6	267
385	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. *New England Journal of Medicine*, **2019**, 381, 727-738	59.2	266
384	PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. *Blood*, **2013**, 122, 2331-7	2.2	255
383	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. *British Journal of Haematology* , **2009**, 144, 895-903	4.5	252
382	Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. *Journal of Clinical Oncology*, **2012**, 30, 1953-9	2.2	244
381	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood*, **2011**, 117, 6063-73	2.2	234
380	Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. *Journal of Clinical Oncology*, **2008**, 26, 4784-90	2.2	227
379	Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. *Blood*, **2007**, 109, 2604-6	2.2	215

378	Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. *Journal of Clinical Oncology*, **2009**, 27, 3518-25	2.2	213
377	An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. *Blood*, **2012**, 119, 5661-70	2.2	209
376	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncology, The*, **2014**, 15, 1503-1512	21.7	207
375	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncology, The*, **2014**, 15, 333-42	21.7	206
374	Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. *Lancet Oncology, The*, **2013**, 14, 1129-1140	21.7	189
373	Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. *Molecular Cell*, **2014**, 53, 534-48	17.6	184
372	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. *Blood*, **2014**, 124, 1038-46	2.2	171
371	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. *Nature Cell Biology*, **2015**, 17, 1484-96	23.4	153
370	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. *Blood*, **2014**, 123, 1461-9	2.2	152
369	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. *Lancet Haematology,the*, **2015**, 2, e516-27	14.6	129
368	Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. *Blood*, **2001**, 97, 2948-56	2.2	119
367	Treatment options for relapsed and refractory multiple myeloma. *Blood*, **2015**, 125, 3085-99	2.2	116
366	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 2039-2051	4.7	114
365	Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. *Journal of Clinical Oncology*, **2011**, 29, 4243-9	2.2	107
364	Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. *Blood Advances*, **2017**, 1, 2105-2114	7.8	103
363	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. *Leukemia and Lymphoma*, **2012**, 53, 1820-3	1.9	103
362	Treatment options for relapsed and refractory multiple myeloma. *Clinical Cancer Research*, **2011**, 17, 1264-77	12.9	103
361	Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. *British Journal of Haematology*, **2007**, 137, 429-35	4.5	103

360	Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. *British Journal of Haematology*, **2017**, 178, 896-905	4.5	101
359	Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. *Blood*, **2016**, 127, 713-21	2.2	99
358	An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 310-8	2	97
357	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. *Molecular Cell*, **2015**, 59, 345-358	17.6	91
356	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1126-1137	2.2	88
355	Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. *British Journal of Haematology*, **2011**, 153, 729-40	4.5	84
354	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. *Cell Metabolism*, **2017**, 25, 358-373	24.6	83
353	Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. *Cancer Chemotherapy and Pharmacology*, **2011**, 67, 57-67	3.5	83
352	A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. *Clinical Cancer Research*, **2010**, 16, 5079-86	12.9	82
351	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. *Cancer*, **2018**, 124, 4032-4043	6.4	82
350	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. *British Journal of Haematology*, **2008**, 143, 222-9	4.5	81
349	Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 402-408.e1	4.7	79
348	Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. *Molecular Cell*, **2014**, 55, 552-65	17.6	78
347	High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2019**, 95, 279-289	4.6	77
346	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. *Blood*, **2011** , 118, 535-43	2.2	70
345	Older patients with myeloma derive similar benefit from autologous transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1796-803	4.7	66
344	How I treat high-risk myeloma. *Blood*, **2015**, 126, 1536-43	2.2	66
343	PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. *Future Oncology*, **2007**, 3, 639-47	3.6	65

342	MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. *Blood*, **2014**, 123, 3269-76	2.2	59
341	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. *Blood Cancer Journal*, **2019**, 9, 94	7	59
340	Daratumumab in multiple myeloma. *Cancer*, **2019**, 125, 2364-2382	6.4	58
339	Current strategies for treatment of relapsed/refractory multiple myeloma. *Expert Review of Hematology*, **2014**, 7, 97-111	2.8	58
338	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1928-1937	2.2	56
337	Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. *JCI Insight*, **2019**, 5,	9.9	55
336	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. *Nature Communications*, **2019**, 10, 1911	17.4	53
335	Review of peripheral neuropathy in plasma cell disorders. *Hematological Oncology*, **2008**, 26, 55-65	1.3	52
334	The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. *Blood*, **2005**, 106, 4322-9	2.2	52
333	MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. *Nucleic Acids Research*, **2017**, 45, 2396-2407	20.1	48
332	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 372-380	2	48
331	Clinical uses of GM-CSF, a critical appraisal and update. *Biologics: Targets and Therapy*, **2008**, 2, 13-27	4.4	48
330	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. *Cancer*, **2019**, 125, 2991-3000	6.4	47
329	Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. *Clinical Pharmacokinetics*, **2017**, 56, 915-924	6.2	46
328	Academic, Foundation, and Industry Collaboration in Finding New Therapies. *New England Journal of Medicine*, **2017**, 376, 1762-1769	59.2	45
327	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. *Expert Review of Anticancer Therapy*, **2015**, 15, 737-48	3.5	43
326	MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. *Cancer Cell*, **2018**, 34, 315-330.e7	24.3	43
325	Current developments in immunotherapy in the treatment of multiple myeloma. *Cancer*, **2018**, 124, 2075-2085	6.4	42

324	Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. *Molecular Cell*, **2016**, 64, 859-874	17.6	42
323	The Tao of myeloma. *Blood*, **2014**, 124, 1873-9	2.2	42
322	Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. *Cancer*, **2006**, 106, 2171-80	6.4	40
321	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *British Journal of Haematology*, **2017**, 178, 571-582	4.5	39
320	Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 370-6	2	39
319	A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. *British Journal of Haematology*, **2017**, 178, 547-560	4.5	38
318	A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. *Biology of Blood and Marrow Transplantation*, **2004**, 10, 848-57	4.7	38
317	Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. *Blood Cancer Journal*, **2020**, 10, 91	7	36
316	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. *Ophthalmology and Therapy*, **2020**, 9, 889-911	5	35
315	Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. *Cancer*, **2013**, 119, 4119-28	6.4	33
314	Relapsed multiple myeloma. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 303-9	3.1	33
313	A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. *Cancer*, **2017**, 123, 4617-4630	6.4	32
312	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. *Lancet Haematology,the*, **2020**, 7, e447-e455	14.6	32
311	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e105-e118	21.7	32
310	Ixazomib for the treatment of multiple myeloma. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 1949-1968	4	32
309	Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma. *Blood*, **2015**, 126, 508-508	2.2	30
308	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. *Leukemia*, **2019**, 33, 1736-1746	10.7	29
307	Safety of proteasome inhibitors for treatment of multiple myeloma. *Expert Opinion on Drug Safety*, **2017**, 16, 167-183	4.1	29

306	New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. *Clinical Cancer Research*, **2016**, 22, 5959-5965	12.9	29
305	Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 466-471.e1	2	29
304	Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. *Expert Opinion on Biological Therapy*, **2013**, 13, 1731-40	5.4	28
303	New cancers after autotransplantations for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 738-45	4.7	28
302	Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. *Cancer*, **2010**, 116, 3143-51	6.4	27
301	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. *Blood Cancer Journal*, **2019**, 9, 3	7	26
300	Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. *Annals of Pharmacotherapy*, **2013**, 47, 1136-42	2.9	26
299	High-risk Multiple Myeloma: Definition and Management. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17S, S80-S87	2	26
298	Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. *British Journal of Haematology*, **2009**, 145, 681-708	4.5	26
297	Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 852-857	4.7	25
296	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. *Journal of Clinical Oncology*, **2020**, 38, 4030-4041	2.2	25
295	Deacetylase inhibitors: an advance in myeloma therapy?. *Expert Review of Hematology*, **2017**, 10, 229-237	2.8	24
294	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. *Nature Communications*, **2020**, 11, 1228	17.4	24
293	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. *Blood*, **2011**, 118, 305-305	2.2	24
292	Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. *Journal of Clinical Oncology*, **2021**, 39, 1139-1149	2.2	23
291	Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. *Cancer*, **2021**, 127, 4198-4212	6.4	23
290	YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. *Journal of Thoracic Oncology*, **2021**, 16, 464-476	8.9	23
289	Racial differences in the incidence and outcomes for patients with hematological malignancies. *Current Problems in Cancer*, **2007**, 31, 182-201	2.3	22

288	Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up. *Blood*, **2015**, 126, 28-28	2.2	22
287	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. *Cancer*, **2019**, 125, 416-423	6.4	22
286	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. *Lancet Oncology, The*, **2021**, 22, 142-154	21.7	22
285	Maintenance therapy in lymphoma. *Clinical Lymphoma and Myeloma*, **2007**, 7, 507-13		21
284	Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).. *Journal of Clinical Oncology*, **2020**, 38, 8536-8536	2.2	20
283	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. *Blood Cancer Journal*, **2020**, 10, 106	7	20
282	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. *Cancer*, **2018**, 124, 4342-4349	6.4	20
281	Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. *Expert Review of Clinical Pharmacology*, **2016**, 9, 35-48	3.8	19
280	Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. *Pharmacological Research*, **2017**, 117, 185-191	10.2	19
279	A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM).. *Blood*, **2006**, 108, 406-406	2.2	19
278	Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. *Journal of Oncology Practice*, **2018**, 14, 414-422	3.1	19
277	HMG-CoA synthase 1 is a synthetic lethal partner of BRAF in human cancers. *Journal of Biological Chemistry*, **2017**, 292, 10142-10152	5.4	18
276	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. *Clinical Pharmacokinetics*, **2018**, 57, 529-538	6.2	18
275	Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. *Expert Opinion on Biological Therapy*, **2005**, 5, 293-311	5.4	18
274	Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. *Oncotarget*, **2016**, 7, 59727-59741	3.3	18
273	Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment	4.7	17
272	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study). *Blood*, **2015**, 126, 4228-4228	2.2	17
271	HLA polymorphism and risk of multiple myeloma. *Leukemia*, **2016**, 30, 2260-2264	10.7	16

270	Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma. *Cancer Informatics*, **2014**, 13, 49-53	2.4	16
269	Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. *Transfusion*, **2007**, 47, 629-35	2.9	16
268	Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. *Journal of Clinical Investigation*, **2019**, 129, 2431-2445	15.9	16
267	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Blood*, **2021**, 137, 3616-3628	2.2	16
266	6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A. *Molecular Cell*, **2019**, 76, 857-871.e9	17.6	15
265	DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling. *Clinical Cancer Research*, **2020**, 26, 3843-3855	12.9	15
264	SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 537-544	2	15
263	Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib. *Blood*, **2008**, 112, 870-870	2.2	15
262	BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. *Oncotarget*, **2016**, 7, 27753-63	3.3	15
261	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. *Journal of Clinical Oncology*, **2016**, 34, 4421-4430	2.2	15
260	Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. *Cancer Letters*, **2018**, 435, 44-54	9.9	14
259	Presentation and risk stratification--improving prognosis for patients with multiple myeloma. *Cancer Treatment Reviews*, **2010**, 36 Suppl 2, S12-7	14.4	14
258	Eliminating the complete response penalty from myeloma response assessment. *Blood*, **2008**, 111, 3297-82	22	14
257	Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation.. *Blood*, **2007**, 110, 1165-1165	2.2	14
256	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). *Blood*, **2013**, 122, 759-759	2.2	14
255	Phase II study of daratumumab (DARA) monotherapy in patients with 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. *Journal of Clinical Oncology* , **2015**, 33, LBA8512-LBA8512	2.2	14
254	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. *British Journal of Haematology*, **2019**, 184, 475-479	4.5	14
253	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. *Cancer Discovery*, **2019**, 9, 756-777	24.4	13

252	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 332-344	2	13
251	Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study **2020**, 8,		13
250	Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low □1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study. *Blood*, **2013**, 122, 285-285	2.2	13
249	Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression. *Blood*, **2014**, 124, 722-722	2.2	13
248	Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis. *Blood*, **2015**, 126, 4222-4222	2.2	13
247	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. *British Journal of Haematology*, **2017**, 179, 66-74	4.5	12
246	Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. *Biologics: Targets and Therapy*, **2013**, 7, 13-32	4.4	12
245	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. *Blood*, **2012**, 120, 202-202	2.2	12
244	ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2015**, 33, 8508-8508	2.2	12
243	Patient-reported outcomes of multiple myeloma patients treated with panobinostat after □ lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. *British Journal of Haematology*, **2018**, 181, 628-636	4.5	12
242	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. *Cancer Biology and Therapy*, **2016**, 17, 769-77	4.6	11
241	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. *British Journal of Haematology*, **2015**, 171, 539-46	4.5	11
240	Novel drug combinations for the management of relapsed/refractory multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14 Suppl, S71-7	2	11
239	Regulation of alloimmune responses by dendritic cell subsets. *Experimental Hematology*, **2008**, 36, 1309-17	3.1	11
238	Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. *Journal of Clinical Investigation*, **2019**, 129, 4110-4123	15.9	11
237	Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. *Blood*, **2012**, 120, 4061-4061	2.2	11
236	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). *Blood*, **2013**, 122, 1969-1969	2.2	11
235	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2014**, 124, 302-302	2.2	11

234	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. *Blood*, **2021**, 137, 3604-3615	2.2	11
233	New Targets and New Agents in High-Risk Multiple Myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e431-41	7.1	11
232	Is there still a role for stem cell transplantation in multiple myeloma?. *Cancer*, **2019**, 125, 2534-2543	6.4	10
231	Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. *Expert Opinion on Biological Therapy*, **2016**, 16, 1291-301	5.4	10
230	Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 657-63	2	10
229	Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. *Clinical Lymphoma and Myeloma*, **2008**, 8, 52-4		10
228	Signal transduction and myeloma: new targets, new hope. *Cancer Biology and Therapy*, **2003**, 2, 310-9	4.6	10
227	Breakthroughs in the management of multiple myeloma. *Drugs*, **2003**, 63, 1621-36	12.1	10
226	Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.. *Blood*, **2008**, 112, 1742-1742	2.2	10
225	Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.. *Blood*, **2009**, 114, 430-430	2.2	10
224	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. *Blood*, **2011**, 118, 1876-1876	2.2	10
223	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,. *Blood*, **2011**, 118, 3976-3976	2.2	10
222	Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial. *Blood*, **2014**, 124, 32-32	2.2	10
221	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). *Blood*, **2014**, 124, 4764-4764	2.2	10
220	Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma: Phase 1b Results (ACY-100 Study). *Blood*, **2015**, 126, 1827-1827	2.2	10
219	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). *Blood*, **2015**, 126, 3036-3036	2.2	10
218	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.. *Journal of Clinical Oncology*, **2013**, 31, 8542-8542	2.2	10
217	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). *Blood Cancer Journal*, **2021**, 11, 103	7	10

216	Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. *Nucleic Acids Research*, **2016**, 44, e69	20.1	9
215	CD86 regulates myeloma cell survival. *Blood Advances*, **2017**, 1, 2307-2319	7.8	9
214	Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 310-3	3.1	9
213	Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. *Leukemia and Lymphoma*, **2006**, 47, 2155-62	1.9	9
212	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. *Blood*, **2011**, 118, 811-811	2.2	9
211	Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2). *Blood*, **2011**, 118, 814-814	2.2	9
210	Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, 8510-8510	2.2	9
209	New Targets and New Agents in High-Risk Multiple Myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, e431-e441	7.1	9
208	Myeloma Is Not a Single Disease. *Journal of Oncology Practice*, **2016**, 12, 287-92	3.1	9
207	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. *Molecular Cell*, **2018**, 69, 923-937.e8	17.6	8
206	Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. *Future Oncology*, **2018**, 14, 3111-3121	3.6	8
205	Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. *Expert Review of Hematology*, **2017**, 10, 933-939	2.8	8
204	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. *Blood*, **2012**, 120, 450-450	2.2	8
203	Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.. *Journal of Clinical Oncology*, **2021**, 39, 8016-8016	2.2	8
202	Induction therapy for newly diagnosed multiple myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 19-28	7.3	7
201	Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2018**, 36, 8040-8040	2.2	7
200	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. *Journal of Clinical Oncology*, **2020**, 38, 8519-8519	2.2	7
199	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. *Blood Cancer Journal*, **2020**, 10, 40	7	7

198	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 356-69	2	6
197	The future of drug development and therapy in myeloma. *Seminars in Oncology*, **2013**, 40, 652-8	5.5	6
196	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. *Lancet Haematology,the*, **2022**, 9, e143-e161	14.6	6
195	Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2020**, 136, 47-48	2.2	6
194	Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). *Blood*, **2020**, 136, 26-27	2.2	6
193	Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.. *Blood*, **2007**, 110, 187-187	2.2	6
192	A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma. *Blood*, **2008**, 112, 3706-3706	2.2	6
191	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). *Blood*, **2010**, 116, 1954-1954	2.2	6
190	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). *Blood*, **2010**, 116, 985-985	2.2	6
189	Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data. *Blood*, **2013**, 122, 3135-3135	2.2	6
188	Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma. *Blood*, **2015**, 126, 29-29	2.2	6
187	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. *Journal of Clinical Oncology* , **2013**, 31, 8517-8517	2.2	6
186	Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38. *Cancer Journal (Sudbury, Mass)*, **2016**, 22, 3-6	2.2	6
185	Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. *PLoS ONE*, **2019**, 14, e0206309	3.7	5
184	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. *Clinical Cancer Research*, **2020**, 26, 2497-2505	12.9	5
183	Sequential or combination therapy for multiple myeloma. *Expert Review of Hematology*, **2012**, 5, 533-45	2.8	5
182	Treatment of relapsed and refractory myeloma. *Current Hematologic Malignancy Reports*, **2009**, 4, 99-107	4.4	5
181	Proteasome inhibition: novel therapy for multiple myeloma. *Oncology Research and Treatment*, **2006**, 29, 162-8	2.8	5

180	Changes in the pattern of TCR V beta repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans. *British Journal of Haematology*, **2001**, 113, 224-30	4.5	5
179	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. *Blood*, **2009**, 114, 132-132	2.2	5
178	Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.. *Blood*, **2009**, 114, 2879-2879	2.2	5
177	Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.. *Blood*, **2009**, 114, 532-532	2.2	5
176	ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. *Blood*, **2011**, 118, 1860-1860	2.2	5
175	Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study. *Blood*, **2011**, 118, 301-301	2.2	5
174	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. *Blood*, **2011**, 118, 634-634	2.2	5
173	Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response. *Blood*, **2016**, 128, 4406-4406	2.2	5
172	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. *Blood Advances*, **2020**, 4, 181-190	7.8	5
171	Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.. *Journal of Clinical Oncology*, **2015**, 33, 8526-8526	2.2	5
170	Antibody treatment in multiple myeloma. *Clinical Advances in Hematology and Oncology*, **2021**, 19, 166-174	0.6	5
169	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. *Advances in Therapy*, **2020**, 37, 1464-1478	4.1	4
168	Novel combination approaches for myeloma. *Hematology American Society of Hematology Education Program*, **2015**, 2015, 286-93	3.1	4
167	Is subcutaneous bortezomib ready for prime time?. *Current Hematologic Malignancy Reports*, **2011**, 6, 73-4	4.4	4
166	Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. *Autophagy*, **2011**, 7, 448-9	10.2	4
165	Improving induction therapy in multiple myeloma. *Current Hematologic Malignancy Reports*, **2010**, 5, 119-28	4.4	4
164	Multiple myeloma: novel approaches for relapsed disease. *Clinical Lymphoma and Myeloma*, **2007**, 8 Suppl 1, S18-23		4
163	Novel treatment approaches for patients with multiple myeloma. *Clinical Lymphoma and Myeloma*, **2006**, 6, 281-8		4

162	A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. *Blood*, **2010**, 116, 1959-1959	2.2	4
161	Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis. *Blood*, **2011**, 118, 1855-1855	2.2	4
160	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2011**, 118, 303-303	2.2	4
159	PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma. *Blood*, **2012**, 120, 1852-1852	2.2	4
158	Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. *Blood*, **2014**, 124, 2120-2120	2.2	4
157	MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide + Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment. *Blood*, **2014**, 124, 4730-4730	2.2	4
156	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).. *Journal of Clinical Oncology*, **2012**, 30, e18572-e18572	2.2	4
155	Phase II study of daratumumab (DARA) monotherapy in patients with ≥3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).. *Journal of Clinical Oncology*, **2015**, 33, LBA8512-LBA8512	2.2	4
154	DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.. *Journal of Clinical Oncology*, **2020**, 38, 8541-8541	2.2	4
153	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. *Lancet Haematology,the*, **2021**, 8, e794-e807	14.6	4
152	Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. *Oncology*, **2011**, 25 Suppl 2, 25-31	1.8	4
151	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 514-8	2	3
150	A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. *Transfusion*, **2013**, 53, 76-84	2.9	3
149	Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. *Transfusion*, **2015**, 55, 2351-7	2.9	3
148	Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, e59-63	2	3
147	Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. *Leukemia and Lymphoma*, **2012**, 53, 725-7	1.9	3
146	Supportive therapies in multiple myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2009**, 7, 971-9	7.3	3
145	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. *Blood*, **2007**, 110, 949-949	2.2	3

144	Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status. *Blood*, **2008**, 112, 3701-3701	2.2	3
143	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). *Blood*, **2010**, 116, 3031-3031	2.2	3
142	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. *Blood*, **2010**, 116, 986-986	2.2	3
141	Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) – a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR). *Blood*, **2011**, 118, 504-504	2.2	3
140	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.. *Journal of Clinical Oncology*, **2013**, 31, 8532-8532	2.2	3
139	Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 797-803	2	3
138	Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 125	7	3
137	Selinexor for the treatment of patients with previously treated multiple myeloma. *Expert Review of Hematology*, **2021**, 14, 697-706	2.8	3
136	Emerging treatments in Castleman disease - a critical appraisal of siltuximab. *Biologics: Targets and Therapy*, **2016**, 10, 9-15	4.4	3
135	Safety and survival outcomes for bloodless transplantation in patients with myeloma. *Cancer*, **2019**, 125, 185-193	6.4	3
134	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. *American Journal of Hematology*, **2021**, 96, E68-E71	7.1	3
133	Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 46-54.e4	2	3
132	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. *Journal of Oncology Practice*, **2018**, 14, 561-564	3.1	3
131	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. *Cancer*, **2018**, 124, 4358-4365	6.4	3
130	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. *Cancers*, **2021**, 13,	6.6	3
129	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.. *Journal of Clinical Oncology*, **2022**, JCO2102257	2.2	3
128	Panobinostat for the treatment of multiple myeloma. *Expert Opinion on Orphan Drugs*, **2015**, 3, 229-238	1.1	2
127	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. *JCO Oncology Practice*, **2020**, 16, e1169-e1180	2.3	2

126	Relapsed and refractory multiple myeloma: new therapeutic strategies. *Hematology/Oncology Clinics of North America*, **2014**, 28, 861-90	3.1	2
125	Down to the bitter end. *Blood*, **2014**, 123, 3061-2	2.2	2
124	Novel treatment approaches for patients with relapsed and refractory multiple myeloma. *Current Treatment Options in Oncology*, **2006**, 7, 246-57	5.4	2
123	Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.. *Lancet Haematology,the*, **2022**, 9, e162-e165	14.6	2
122	Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. *Blood*, **2018**, 132, 3294-3294	2.2	2
121	Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study. *Blood*, **2019**, 134, 1872-1872	2.2	2
120	A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg) for Advanced MDS and Secondary or Relapsed AML.. *Blood*, **2004**, 104, 1814-1814	2.2	2
119	Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation.. *Blood*, **2007**, 110, 1520-1520	2.2	2
118	Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.. *Blood*, **2009**, 114, 2865-2865	2.2	2
117	Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.. *Blood*, **2009**, 114, 3890-3890	2.2	2
116	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. *Blood*, **2010**, 116, 1952-1952	2.2	2
115	The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs),. *Blood*, **2011**, 118, 3994-3994	2.2	2
114	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. *Blood*, **2013**, 122, 1924-1924	2.2	2
113	Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective. *Blood*, **2015**, 126, 4254-4254	2.2	2
112	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2013**, 31, 8584-8584	2.2	2
111	The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.. *Journal of Clinical Oncology*, **2015**, 33, TPS8613-TPS8613	2.2	2
110	Treatment of MM: Upcoming Novel Therapies. *Cancer Treatment and Research*, **2016**, 169, 195-205	3.5	2
109	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. *Molecular Cell*, **2021**, 81, 3833-3847.e11	17.6	2

108	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. *Blood Cancer Discovery*, **2021**, 2, 600-615	7	2
107	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discovery*,OF1-OF12	7	2
106	Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin. *Experimental Hematology*, **2012**, 40, 95-6	3.1	1
105	Practical considerations for multiple myeloma: an overview of recent data and current options. *Clinical Lymphoma and Myeloma*, **2008**, 8 Suppl 4, S144-8		1
104	When the same is really different. *Blood*, **2006**, 108, 3233-3234	2.2	1
103	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. *Blood*, **2018**, 132, 3241-3241	2.2	1
102	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. *Blood*, **2018**, 132, 2157-2157	2.2	1
101	Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2020**, 136, 22-23	2.2	1
100	Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study. *Blood*, **2020**, 136, 4-6	2.2	1
99	Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phos-PDK1 in Human Lymphoma and Leukemia Cell Lines.. *Blood*, **2005**, 106, 1488-1488	2.2	1
98	Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines.. *Blood*, **2005**, 106, 1568-1568	2.2	1
97	T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoetic Progenitor Cell Transplantation (HPCT).. *Blood*, **2006**, 108, 3224-3224	2.2	1
96	Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma.. *Blood*, **2007**, 110, 3605-3605	2.2	1
95	Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.. *Blood*, **2007**, 110, 3612-3612	2.2	1
94	A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.. *Blood*, **2008**, 112, 3332-3332	2.2	1
93	FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation. *Blood*, **2008**, 112, 3722-3722	2.2	1
92	The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.. *Blood*, **2009**, 114, 1689-1689	2.2	1
91	Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).. *Blood*, **2009**, 114, 1827-1827	2.2	1

90	Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.. *Blood*, **2009**, 114, 1845-1845	2.2	1
89	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. *Blood*, **2010**, 116, 1937-1937	2.2	1
88	Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis. *Blood*, **2011**, 118, 1882-1882	2.2	1
87	Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. *Blood*, **2011**, 118, 3959-3959	2.2	1
86	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,. *Blood*, **2011**, 118, 3968-3968	2.2	1
85	Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT). *Blood*, **2011**, 118, 824-824	2.2	1
84	The Multiple Myeloma Research Foundation (MMRF) CoMMpassSM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes. *Blood*, **2012**, 120, 3980-3980	2.2	1
83	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. *Blood*, **2012**, 120, 4079-4079	2.2	1
82	Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM).. *Journal of Clinical Oncology*, **2013**, 31, 8540-8540	2.2	1
81	Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis.. *Journal of Clinical Oncology*, **2013**, 31, 8609-8609	2.2	1
80	Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).. *Journal of Clinical Oncology*, **2018**, 36, 8050-8050	2.2	1
79	Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. *Blood*, **2021**, 138, 2746-2746	2.2	1
78	Maintenance Therapy in Multiple Myeloma **2008**, 91-98		1
77	Multiple myeloma immunoglobulin translocations portend poor prognosis		1
76	Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis. *Blood*, **2019**, 134, 1805-1805	2.2	1
75	Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.. *Blood*, **2009**, 114, 3888-3888	2.2	1
74	The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). *Blood*, **2011**, 118, 2935-2935	2.2	1
73	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. *British Journal of Cancer*, **2020**, 123, 1228-1234	8.7	1

72	Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 701-710	2	1
71	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 3178-3189	12.9	1
70	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. *Clinical Pharmacology: Advances and Applications*, **2021**, 13, 169-180	1.5	1
69	Future directions in immunomodulatory therapy. *Medical Oncology*, **2010**, 27 Suppl 1, S62-6	3.7	0
68	Safety and Efficacy of Evomela in Myeloma Autotransplants. *Blood*, **2018**, 132, 3446-3446	2.2	0
67	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. *Journal of Clinical Oncology*, **2013**, 31, 8588-8588	2.2	0
66	Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function. *Blood*, **2018**, 132, 951-951	2.2	0
65	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. *Blood*, **2010**, 116, 1963-1963	2.2	0
64	Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor,. *Blood*, **2011**, 118, 3950-3950	2.2	0
63	Autologous hematopoietic transplant in multiple myeloma **2017**, 194-206		
62	Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. *Cancer*, **2019**, 125, 2322-2324	6.4	
61	Reply to N. Biran et al. *Journal of Clinical Oncology*, **2020**, 38, 1368-1369	2.2	
60	Treatment of emergent peripheral neuropathy in plasma cell disorders245-254		
59	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. *Blood and Lymphatic Cancer: Targets and Therapy*, **2013**, 41	2.6	
58	Putting the E (evidence) in a new Era for myeloma. *Leukemia and Lymphoma*, **2011**, 52, 349-50	1.9	
57	The White House crusade against ... MGUS?. *Blood*, **2010**, 116, 1020-1	2.2	
56	MAINTENANCE THERAPY IN MULTIPLE MYELOMA37-45		
55	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. *Blood*, **2020**, 136, 20-21	2.2	

54	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. *Blood*, **2020**, 136, 31-32	2.2
53	Role of clonoSEQ , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. *Blood*, **2020**, 136, 50-51	2.2
52	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. *Blood*, **2021**, 138, 1616-1616	2.2
51	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. *Blood*, **2021**, 138, 2733-2733	2.2
50	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. *Blood*, **2021**, 138, 1624-1624	2.2
49	Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities. *Blood*, **2021**, 138, 4958-4958	2.2
48	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. *Blood*, **2021**, 138, 1611-1611	2.2
47	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR). *Blood*, **2021**, 138, 2758-2758	2.2
46	Donor Dendritic Cells Regulate Immune Reconstitution after Allogeneic Bone Marrow Transplantation.. *Blood*, **2004**, 104, 3073-3073	2.2
45	Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation.. *Blood*, **2004**, 104, 3159-3159	2.2
44	Patient Characteristics in CD 20+ and CD 20 Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis.. *Blood*, **2005**, 106, 4523-4523	2.2
43	Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen.. *Blood*, **2005**, 106, 4634-4634	2.2
42	Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL.. *Blood*, **2005**, 106, 2016-2016	2.2
41	Infliximab for the Treatment of Chronic Graft Versus Host Disease.. *Blood*, **2006**, 108, 2889-2889	2.2
40	Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data.. *Blood*, **2006**, 108, 1960-1960	2.2
39	Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.. *Blood*, **2006**, 108, 3065-3065	2.2
38	p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma.. *Blood*, **2007**, 110, 253-253	2.2
37	The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD.. *Blood*, **2007**, 110, 1912-1912	2.2

36	Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070.. *Blood*, **2007**, 110, 2920-2920	2.2
35	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. *Blood*, **2018**, 132, 3302-3302	2.2
34	Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells. *Blood*, **2014**, 124, 4726-4726	2.2
33	Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.. *Journal of Clinical Oncology*, **2015**, 33, e19538-e19538	2.2
32	Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study.. *Journal of Clinical Oncology*, **2015**, 33, 8575-8575	2.2
31	Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study. *Blood*, **2008**, 112, 3644-3644	2.2
30	Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease. *Blood*, **2008**, 112, 1183-1183	2.2
29	The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma.. *Blood*, **2009**, 114, 1408-1408	2.2
28	Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.. *Blood*, **2009**, 114, 53-53	2.2
27	A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.. *Blood*, **2009**, 114, 3851-3851	2.2
26	A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation.. *Blood*, **2009**, 114, 4230-4230	2.2
25	Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma.. *Blood*, **2009**, 114, 3879-3879	2.2
24	The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma **2011**, 69-77	
23	Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. *Blood*, **2010**, 116, 1942-1942	2.2
22	High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM). *Blood*, **2010**, 116, 1355-1355	2.2
21	Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth. *Blood*, **2010**, 116, 3142-3142	2.2
20	Thrombocytopenia Induced by Combination Administration of Romidepsin and Bortezomib In Mice Is Rapidly Reversible After Drug Treatment. *Blood*, **2010**, 116, 4909-4909	2.2
19	Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma. *Blood*, **2011**, 118, 2891-2891	2.2

18	Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis. *Blood*, **2011**, 118, 1959-1959	2.2
17	Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial. *Blood*, **2011**, 118, 2988-2988	2.2
16	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. *Blood*, **2011**, 118, 1875-1875	2.2
15	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. *Blood*, **2011**, 118, 815-815	2.2
14	ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma. *Blood*, **2011**, 118, 2884-2884	2.2
13	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. *Blood*, **2011**, 118, 1024-1024	2.2
12	Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes. *Blood*, **2011**, 118, 1377-1377	2.2
11	Validation of the Function of 14-3-3 in Multiple Myeloma (MM). *Blood*, **2011**, 118, 1369-1369	2.2
10	MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells. *Blood*, **2011**, 118, 1870-1870	2.2
9	Prioritizing Content in Continuing Hematologic Oncology Education: A Survey of 51 Clinical Investigators. *Blood*, **2012**, 120, 4270-4270	2.2
8	Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets.. *Blood*, **2012**, 120, 2953-2953	2.2
7	Pre-Transplant Salvage Therapy Prior to Autologous Transplant (AHCT) in Patients Not Responding to Initial Induction for Multiple Myeloma (MM). *Blood*, **2012**, 120, 597-597	2.2
6	Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.. *Journal of Clinical Oncology*, **2013**, 31, 7035-7035	2.2
5	Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).. *Journal of Clinical Oncology*, **2013**, 31, 8531-8531	2.2
4	AKT inhibitors in multiple myeloma **2013**, 104-113	
3	Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC). *Blood*, **2013**, 122, 3148-3148	2.2
2	We need CD38 STAT-JAK. *Blood*, **2020**, 136, 2246-2248	2.2
1	Frontline regimens for multiple myeloma patients. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 331-2	0.6